ClinicalTrials.gg
RecruitingNCT07546240ORHEELSUpdated Apr 22, 2026

Optimal Radiotherapy - Heel Spur Syndrome - Randomized Clinical Trial

An interventional study of Standard fractioned dose and Reduced fractioned dose in Heel Spur Syndrome, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Recruiting at 1 site in Poland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Heel Spur Syndrome (HSS), is a pathology characterized by chronic inflammation and degenerative changes that affect approximately 10% of adults. Although many patients respond to conservative care, about 30% experience persistent pain. Low-dose radiation therapy (LDRT) is a well-established European method with proven anti-inflammatory and immunomodulatory effects. The ORHEELS trial aims to assess whether a Polish standard dose of 6 Gy in 6 daily fractions (fx)(5 times/week) is not inferior to the treatment with total dose of 3 Gy / fx 0,5 Gy /fractionated twice weekly. The study is designed to assess the impact of intensity of treatment (daily (5 times / week) versus twice weekly fractionation) on clinical outcomes.

Read the detailed description

The aim of this study is to optimize the fractionation schedules for radiotherapy in the treatment of HSS, through a prospective randomized non-inferiority clinical trial conducted at Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland.

Purpose/Objective:

  • To evaluate whether the Polish standard dose (6 Gy) achieves non-inferior therapeutic effects compared to the current European Standard Dose (3 Gy).
  • To investigate whether daily fractionation is more effective than twice weekly fractionation in maintaining the desired immunomodulatory effect and avoiding a pro-inflammatory "rebound".
  • To minimize the risk of stochastic effects (secondary cancers) by halving the cumulative radiation dose.
02

Conditions studied

  • Heel Spur Syndrome

Keywords

  • Heel spur
  • Plantar fasciitis
  • Low-dose radiotherapy
  • Anti-inflammatory radiotherapy
03

In context

Fasciitis, Plantar

224 studies on the registry are indexed under Fasciitis, Plantar; 59 are open to participants now.

This study's planned enrollment of 366 is above the median of 56 across 194 interventional studies indexed under Fasciitis, Plantar.

Browse Fasciitis, Plantar studies →

Lead sponsor

Maria Sklodowska-Curie National Research Institute of Oncology is the lead sponsor of 64 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients aged 40 years or older.
  • Clinically confirmed painful Heel Spur Syndrome (plantar fasciitis) persisting for at least 3 months
  • No effect from previous orthopaedic, physical, or analgesic treatments.
  • General performance status ZUBROD 0-3.
  • Exclusion of other local conditions.
  • Patient readiness for follow-up contact.

Exclusion Criteria:

  • Prior radiotherapy for heel spur.
  • Local use of within 4 weeks before planned radiotherapy.
  • Previous trauma, surgery to the foot on the same side.
  • Systemic diseases (eg collagen vascular disease).
  • Pregnancy or breastfeeding.
  • Lack of written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
366 participants (estimated)

Study arms

  • Experimental
    Arm A

    Polish Standard Dose

    Radiation: Standard fractioned dose

  • Experimental
    Arm B

    Arm B (Reduced Dose)

    Radiation: Reduced fractioned dose

  • Other
    Arm C

    (Reduced Dose \& Intensity)

    Radiation: Reduced fractioned dose & Intensity

Interventions

  • RadiationStandard fractioned dose

    Total dose of 6 Gy (6 fractions of 1.0 Gy) administered 5 times per week

  • RadiationReduced fractioned dose

    Total dose of 3 Gy (6 fractions of 0.5 Gy) administered 5 times a week.

  • RadiationReduced fractioned dose & Intensity

    Total dose of 3 Gy (6 fractions of 0.5 Gy) administered 2 times per week

06

What researchers measure

Primary outcomes

  1. Non-inferiority of reduced fraction dose radiotherapy of heel spur

    The primary endpoint will be evaluated as the difference in treatment success rates between arms A and C and between arms B and C. Success of treatment will be defined as a ≥50% reduction in pain intensity measured using the VAS scale and assessed 3 months after the end of treatment using the Pannewitz-modified pain scale relative to the baseline. Analyses for the two equivalent non-inferiority comparisons (A vs. C and B vs. C) will be performed one-sided at a significance level of α = 0.0125 (after applying the Bonferroni correction), corresponding to 97.5% two-sided confidence intervals, assuming a success rate of 65% for all three treatment regimens and an acceptable non-inferiority margin of δ=0.2, expressed as a risk difference

    Time frame: 3 months after treatment

Secondary outcomes

  1. Assessment of effectiveness in pain relief

    Pain relief will be evaluated using: The Visual Analogue Scale (VAS) and The modified von Pannewitz pain scale.

    Time frame: 3, 6, 12 and 24 months after treatment

  2. Assessment of functional and gait improvement

    Improvement will be measured using the Rowe Score scale.

    Time frame: Before and 3, 6 and 12 months after treatment

  3. Reirradiation rate

    A comparison of the number of patients requiring reirradiation defined as the proportion of patients requiring a second course of radiotherapy within 12 months of initial treatment

    Time frame: Up to 12 months after treatment

  4. Assessment of treatment safety and tolerability

    The skin toxicity evaluated according to the version 5 of the Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: Throughout the observation period

  5. Patients' reported Quality of Life

    Evaluation of the SF-36 questionnaires

    Time frame: Before and 6, 12 months after the treatment

  6. Evaluation of inflammatory markers

    Evaluation of systemic inflammation (morphology, CRP, IL-6, fibrinogen, and TNF-α)

    Time frame: Before treatment and 1 month after treatment

  7. Assessment of treatment effectiveness

    The assessment will be conducted in accordance with the definitions provided, depending on the size of the irradiated area and the duration of pain symptoms (less than or more than 6 months)

    Time frame: 3, 6 and 12, 24 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Niewald M, et al. Randomized Multicenter Trial on the Effect of Radiotherapy on Plantar Fasciitis (Painful Heel Spur) using Very Low Doses: Mature Results after 12 Months' Follow-up. International Journal of Radiation Oncology, Biology, Physics. 2025;81(2):S39-S40.
  • Seegenschmiedt MH, Makoski H-B, Trott KR, Brady LW, editors. Radiotherapy for Non-Malignant Disorders: Contemporary Concepts and Clinical Results. Berlin-Heidelberg-New York: Springer; 2008.
  • Bulstrode C. Oxford Textbook of Orthopaedics and Trauma. Oxford: Oxford University Press; 2002.
  • Burkon P, Slavik M, Kazda T, Slampa P, Bobek L, et al. Heel Spur Radiotherapy: Prospective Randomized Clinical Trial. International Journal of Radiation Oncology, Biology, Physics. 2025;123(1):e628-e629
  • Chow S-C, Shao J, Wang H, Lokhnygina Y. Sample Size Calculations in Clinical Research. Third ed: Chapman and Hall/CRC; 2017
  • Alvarez B, Montero A, Hernando O, Ciervide R, Garcia J, Lopez M, Garcia-Aranda M, Chen X, Flores I, Sanchez E, Valero J, Prado A, Alonso R, Alonso L, Fernandez-Leton P, Rubio C. Radiotherapy CT-based contouring atlas for non-malignant skeletal and soft tissue disorders: a practical proposal from Spanish experience. Br J Radiol. 2021 Aug 1;94(1124):20200809. doi: 10.1259/bjr.20200809. PubMed 34282948 ↗
  • Mucke R, Schonekaes K, Micke O, Seegenschmiedt MH, Berning D, Heyder R. Low-dose radiotherapy for painful heel spur. Retrospective study of 117 patients. Strahlenther Onkol. 2003 Nov;179(11):774-8. doi: 10.1007/s00066-003-1126-9. PubMed 14605748 ↗
  • Rodel F, Frey B, Gaipl U, Keilholz L, Fournier C, Manda K, Schollnberger H, Hildebrandt G, Rodel C. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr Med Chem. 2012;19(12):1741-50. doi: 10.2174/092986712800099866. PubMed 22414082 ↗
  • Miszczyk L, Wozniak G, Jochymek B, Trela K, Urban A. [Evaluation of the effectiveness of the calcaneal spurs radiotherapy]. Chir Narzadow Ruchu Ortop Pol. 2003;68(3):191-5. Polish. PubMed 14564798 ↗
  • Canyilmaz E, Canyilmaz F, Aynaci O, Colak F, Serdar L, Uslu GH, Aynaci O, Yoney A. Prospective Randomized Comparison of the Effectiveness of Radiation Therapy and Local Steroid Injection for the Treatment of Plantar Fasciitis. Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):659-66. doi: 10.1016/j.ijrobp.2015.02.009. Epub 2015 Apr 28. PubMed 25936814 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2030, 47 months after the start.

Of 104 non-industry interventional studies with no phase under Fasciitis, Plantar, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's planned 47 months is above that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 22, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Mar 22, 2030
CompletionEst.
Mar 22, 2030
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07546240
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Mar 23, 2026
Primary completion
Mar 22, 2030 (estimated)
Completion
Mar 22, 2030 (estimated)
Last update
Apr 22, 2026

Study contacts

Iwona Dębosz-Suwińska
Contact
iwona.debosz-suwinska@gliwice.nio.gov.pl
+48232789148
Mateusz Gajek
Contact
mateusz.gajek@gliwice.nio.gov.pl
+48322788063
Iwona Dębosz-Suwińska
principal investigator · Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion